Clinical Trials Logo

Acquired Pure Red Cell Aplasia clinical trials

View clinical trials related to Acquired Pure Red Cell Aplasia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06412497 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

NCT ID: NCT04423367 Terminated - Clinical trials for Acquired Pure Red Cell Aplasia

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

BID-PERAL
Start date: September 13, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.